Abstract
Correct phenotypic interpretation of variants of unknown significance for cancer-associated genes is a diagnostic challenge as genetic screenings gain in popularity in the next-generation sequencing era. The Critical Assessment of Genome Interpretation (CAGI) experiment aims to test and define the state of the art of genotype-phenotype interpretation. Here, we present the assessment of the CAGI p16INK4a challenge. Participants were asked to predict the effect on cellular proliferation of 10 variants for the p16INK4a tumor suppressor, a cyclin-dependent kinase inhibitor encoded by the CDKN2A gene. Twenty-two pathogenicity predictors were assessed with a variety of accuracy measures for reliability in a medical context. Different assessment measures were combined in an overall ranking to provide more robust results. The R scripts used for assessment are publicly available from a GitHub repository for future use in similar assessment exercises. Despite a limited test-set size, our findings show a variety of results, with some methods performing significantly better. Methods combining different strategies frequently outperform simpler approaches. The best predictor, Yang&Zhou lab, uses a machine learning method combining an empirical energy function measuring protein stability with an evolutionary conservation term. The p16INK4a challenge highlights how subtle structural effects can neutralize otherwise deleterious variants.
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INTRODUCTION
As genetic tests become routinely applied to the investigation of disease-associated variants, relevant efforts are made by the scientific community to develop computational tools for genetic variant evaluation (Niroula & Vihinen, 2016) . A number of methods presenting different strategies have been presented, and their application is becoming a common routine in cancer research (Kannengiesser et al., 2009; Miller et al., 2011) . In silico predictors are generally designed to provide a fast simplified response when compared with experimental screening protocols. However, lack of properly validated benchmarking represents the main limiting factor hampering wider application in a clinical scenario (Walsh, Pollastri, & Tosatto, 2016) . Variants affecting tumor-suppressor genes, such as TP53 (Liu & Bodmer, 2006) , VHL (Leonardi, Martella, Tosatto, & Murgia, 2011) , and CDKN2A (Scaini et al., 2014) are actively investigated and collected in freely accessible databases (Forbes et al., 2015; Tabaro et al., 2016; Wang et al., 2015) . However, the correct interpretation of their pathogenic significance is far from definitively addressed. One relevant issue remains our ability to correctly predict disease-causing gene variants among variants of unknown significance (VUS) (Wang & Shen, 2014) . Correct prediction of susceptibility variants can foster the identification of molecular pathways causative of human diseases, particularly when variants affect well-understood genes previously validated by functional studies (Manolio, 2010) . Since 2010, the Critical Assessment of Genome Interpretation (CAGI) experiment tries to objectively assess the state of the art of computational tools developed for genotypephenotype determination. Here, we present a critical assessment of pathogenicity predictors applied to variants from the CDKN2A (MIM# 600160) tumor suppressor, also known as p16. CDKN2A is the major susceptibility gene identified in familial malignant melanoma. Approximately 40% of melanoma-prone families worldwide have CDKN2A germline variants (Hussussian et al., 1994) . The CDKN2A locus maps to chromosome 9p21 and its regulation is particularly complex, involving alternative promoters, splicing, and reading frames of shared coding regions. Two structurally unrelated tumor suppressors, p16INK4a and p14ARF, involved in cell cycle regulation, are coded by alternative splicing of different first exons (1-and 1-). p16INK4a is a cyclin-dependent kinase (CDK4/6) inhibitor and p14ARF acts in TP53 stabilization, binding, and sequestering the MDM2 proto-oncogene (Serrano, Hannon, & Beach, 1993; Zhang, Xiong, & Yarbrough, 1998) . Thus, alterations of this single locus compromises two important tumor-suppressor pathways at the same time (Andreotti et al., 2016; Aoude, Wadt, Pritchard, & Hayward, 2015) .
When associated with D-type cyclins, CDK4/6 promotes cell cycle progression through the G1 phase by contributing to the phosphorylation and functional inactivation of retinoblastoma-associated protein (Sherr, 1994; Weinberg, 1995) . Structurally, p16INK4a consists of four repeated ankyrin-type motifs, composed of two antiparallel helices and a loop forming the CDK4/6-binding interface (Fig. 1 ).
In the context of pathogenicity prediction, the ankyrin fold is challenging. Ankyrin repeats stack against one another to form a unique elongated single domain, with a multistate folding pathway conferring high structural plasticity. This highly modular nature confers unique characteristics such as a high affinity for protein-protein interactions (Tang, Guralnick, Wang, Fersht, & Itzhaki, 1999) . However, stack modularity can also be seen as a gradient of transiently folded states, where a single amino acid substitution may be able to interrupt p16INK4a-specific periodicity, causing a severe perturbation of the entire protein structure (Peng, 2004) . For this CAGI challenge, F I G U R E 1 Overview of CDK6-P16INK4A tumor-suppressor complex. Cartoon representations of the p16INK4a 3D structure (PDB code 1BI7) colored blue, whereas CDK6 is presented as full surface (light gray). Magenta spheres represent positions of variants considered for the challenge mapped on its surface. The ankyrin repeats composing p16INK4a structure are presented below with a schematic representation of mutated amino acid positions (magenta spots). Variant nomenclature refers to CDKN2A mRNA isoform1 (GenBank identifier: NM_000077.4); nucleotide numbering starts with the A of the ATG translation initiation site.
participants were asked to predict the effect of 10 CDKN2A variants in the p16-challenge, previously validated in cell proliferation rate assays. Twenty-two predictions using different strategies, for example, scoring functions based on sequence conservation, or machine learning predictors, were assessed. The results allow us to propose where pathogenicity prediction might be improved, as methods combining information from different strategies were found to have the most promising results.
METHODS

Dataset and classifications
The challenge includes 10 nucleotide variants affecting only the CDKN2A gene-coding region without interfering with p14ARF. Each variant codes for a single amino acid substitution, with no insertions or deletions. The variant nomenclature used in this work refers to CDKN2A mRNA isoform1 (GenBank identifier: NM_000077.4). Participants were requested to perform predictions of the cellular proliferation rate for each of the 10 mutant proteins as a percentage of the proliferation rate relative to pathogenic mutants (Table 1) . A proliferation rate of 100% is used for pathogenic variants (positive controls), and 50% for wild-type-like variants (negative controls). Predictors were also allowed to specify a prediction confidence (standard deviation) for each variant, with a maximum of six alternative submissions per group. The standard deviation was only reported for 14 submissions, and the same confidence value was used for all predictions in five submissions. In a few cases, predictions have been manually rescaled during assessment as proliferation levels were wrongly reported as a fraction of 1 rather than 100 (where 100 represents the 100% posi- Identifiers of variants affecting cell proliferation and relative proliferation level. Variant nomenclature refers to CDKN2A mRNA isoform1 (GenBank identifier: NM_000077.4); nucleotide numbering starts with the A of the ATG translation initiation site. Proliferation levels were rescaled between 0.5 (wild-type-like phenotypes) and 1 (tumor-like phenotypes).
TA B L E 1 p16INK4a proliferation rate test set
tive control proliferation rate). A training set composed of 19 CDKN2A
variants from Kannengiesser et al. (2009) and Miller et al. (2011) was also provided to the participants for training (Supp . Table S1 ). This choice was justified based on the similar use of bioinformatics tools to predict CDKN2A variant effects on cell proliferation as verified by experimental assays. Bioinformatics predictions were described to be comparable with verified real values for most variants (Kannengiesser et al., 2009; Miller et al., 2011) . Real proliferation levels obtained from the literature were rescaled between 0.5 and 1 (proliferation level of wild-type and disease-like phenotypes, respectively).
In vitro proliferation assay of CDKN2A variants and data normalization
The experimental validation of the pathogenic effect of the variants used in CAGI is described in detail in Scaini et al. (2014 
Performance assessment
Evaluating the performance of bioinformatics tools in predicting VUS impact is a non-trivial task. The assessment should not be seen as a mere discrimination of winners/losers, but rather aim at identifying which tool generated the most reliable prediction. A considerable num- Table 3 , and additional performance measures at different thresholds can be found in Supp. Table S3 . An overall ranking of predictors' performance was defined as average ranking of four quality measures. All measures are defined in more detail in the Supp. Material. To assess the statistical significance of each performance index, 10,000 random predictions were generated and used to calculate an empirical continuous probability (score s), with a P value defining the proportion of random predictions scoring > s. The R scripts used to perform the assessment are publicly available from the GitHub repository at URL: https://github.com/BioComputingUP/CAGI-p16-assessment.
RESULTS
Participation and similarity between predictions
In the p16INK4a CAGI challenge, participants were requested to predict the effects of 10 p16INK4a VUS potentially causing malignant proliferation validated with cellular proliferation assays (Scaini et al., 2014 ). This challenge attracted 22 submissions from 10 participating groups, which were assessed without knowing the identity of the predictors. After the assessment was completed, only one group remained anonymous. Table 2 lists the participating groups, their submission IDs, and main features used for prediction. The majority of methods used evolutionary information derived from multiple-sequence alignments for prediction. Several methods also used the available crystal structure of p16INK4a bound to CDK6 (see Fig. 1 ) to calculate folding energies. Combinations of both approaches or of different predictors were also submitted. A summary for each method is described in the Supp.
Material. Of the 10 participating groups, four contributed one prediction, one submitted two, four submitted three, and only one group submitted four different submissions.
An analysis of prediction similarity was performed to better highlight the peculiarity of each submission (see Suppl. Fig. S1 for the full dataset). Almost all groups performing multiple submissions made very similar predictions (see Fig. 2 ). This is particularly evident for the Bromberg group, which were de facto mostly identical for many The Vihinen lab (submissions 6, 13) presents a weak anticorrelation among its predictions, probably due to predictions for all except one variant being very high (≥0.85). The four submissions from Yang&Zhou lab (10, 16, 21, 22) present almost no correlation, possibly also due to a sign error affecting three submissions.
Assessment criteria and performance measures
The type of insights to be gained from assessing a CAGI challenge depends strongly on the criteria used for evaluation. As this is a relatively novel field, extra care was given to this point. Ideally, the criteria should reflect the true performance of the methods, highlighting better how related the assessment criteria are among each other, their correlation was plotted (Fig. 3) . The PCC and KCC correlation coefficients are highly correlated with each other and with the three AUC measures. RMSE and two PWSD variants are less correlated and offer two alternative views of the data.
TA B L E 2 Predictor overview
Using a reduced set of measures for the final ranking is suggested by the high pairwise correlation coefficients, suggesting they are measuring very similar features (see Fig. 3 ). A ranking including largely orthogonal measures should prove more robust and informative. For this reason, only four measures (one for each group) with low pairwise correlation were considered for the final ranking, that is, KCC, RMSE, AUC considering a 75% of proliferation threshold (AUC75), and PWSD considering a standard deviation of 10% for all submission (PWSD10). In particular, KCC was chosen as it is a rank-based measure appropriate when targets are continuous and their relative order is critical. The data provider recommended to use AUC75, as the corresponding proliferation level appeared to be the best threshold to separate pathogenic and neutral phenotypes. Finally, PSWD10 was preferred over PSWD as many predictors did not report standard deviation for their submissions.
Performance evaluation
The assessment of performance achieved by the 22 methods showed many predictions to have good results on average. This is particularly Results are shown for the main performance indices considered in the assessment. The top performing submission in each category is shown in bold and the second best is underlined.
TA B L E 3 Performance indices
Submission
true considering AUC75, where most of the submissions achieved values between 0.7 and 1. For KCC, the average of the submissions shows a moderate to strong correlation with real data (see Table 3 ).
Good results were however not sufficient for most predictions to be statistically significant. Very demanding thresholds emerged to separate significant results from random for this challenge, with only the top ranking methods being significant for most of the four performance indices (see below). This is probably due to the limited number of variants present in the test set, where wrong prediction of one variant corresponds to 10% of the dataset. Small variations in predictions could be reflected in remarkable fluctuation of performance indices due to the small number of variants considered. To perform a global assessment of predictor performance, we therefore decided to focus more on ranking than on numerical values achieved for each measure. Ranking variations not only may better reflect the magnitude of performance variation, but can also be considered more intuitive for nonspecialist readers. The Yang&Zhou lab (submission 10) performed best, ranking first in all performance indices except AUC75, where it is fifth (see Table 4 ). The Lichtarge lab (submission 4), an anonymous prediction was used to test whether the performance achieved by the three best submissions could be achieved by chance. Submission 10 performs better than random (P value < 0.05) for three out of four measures, the only exception being PSWD10. Submissions 4 and 5 perform better than random only considering KCC and AUC75 (see Table 5 ). The P value for random predictions scoring better using each assessment metric is shown over 10,000 simulations. P values < 0.05 are shown as bold.
TA B L E 4 Submission ranking
Rank
Difficult variants
An analysis of submissions shows prediction reliability to depend on position, with p.Gly23Ser, p.Gly35Glu, and p.Gly35Arg being particularly complex to address (see Supp. Table S2 ). p.Gly23Ser and p.Gly35Arg are the most mispredicted variants using PWSD10, with only two correct predictions. Both variants affect conserved positions that are known to have role in correct p16INK4a folding and CDK inhibition. A previous study (Scaini et al., 2014) addressing the same genetic changes showed p.Gly23Ser to introduce a weak interaction with S56. Although weak, this is thought to stabilize the overall fold, inducing a small local rearrangement of the p16-CDK4/6-binding interface. Predictions seem to miss this twofold effect. The p.Gly23Ser variant is mainly predicted as damaging, suggesting that current methods overpredict a pathogenic effect. A similar scenario can be seen for p.Gly35Glu and p.Gly35Arg. The G35 is a solvent-exposed residue, which localizes at the end of the first -helix in the p16INK4a structure.
Substitution of G35 with charged residues can be accommodated in the ankyrin fold, likely yielding neutral phenotypes (Scaini et al., 2014) mispredicted in this case. The only notable exception is submission 20, which shows the best accuracy with these difficult variants but misses most of the other variants. The p16INK4a challenge shows how different variants on the same residue can have widely diverging effects, which are not well predicted by many submissions.
p16INK4a/CDK4/6-binding interface (Miller et al., 2011; Scaini et al., 2014) . For a generic pathogenicity predictor, this may be the worst case scenario. Sequence conservation analysis highlights the residue as conserved and relevant for protein structure, but may miss the pathogenic effect caused by interference at the protein-protein interaction interface. More advanced approaches, such as HMMs and neural networks, turned out to be the best strategies for this specific problem. It can be argued that the limited number of variants composing the dataset may limit generalization of the results and a larger set of variants might produce a different ranking. The dataset was chosen to represent a balanced ratio between pathogenic and neutral variants. Despite these intrinsic limitations, we believe this challenge may be representative of a clinical setting, where disease-associated genes are poorly described when it comes to variants found in patients. It is evident from the assessment that no method is able to perform errorless predictions.
We expect the CAGI results to provide a starting point to improve the available methods and encourage using the scripts available on GitHub to help standardize the assessment.
